ED:NYSEConsolidated Edison, Inc. Analysis
Data as of 2026-03-10 - not real-time
$111.80
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Consolidated Edison (ED) is trading at $111.8, just below its DCF‑derived fair value of $113.9, indicating a modest fair‑valued position. The 20‑day SMA ($111.34) sits just under the current price, while the 50‑day and 200‑day SMAs ($106.18 and $101.70) are well below, confirming a bullish longer‑term trend. Momentum indicators are mixed: RSI is at 57, suggesting neither overbought nor oversold conditions, and the MACD histogram is negative, flagging short‑term bearish pressure despite an overall bullish direction. Volume is increasing, supporting the price advance toward the $115.25 resistance level. The company posted an earnings beat in Q4, with EPS of $0.89 versus the $0.84 consensus, and announced a common share offering that could bolster balance‑sheet flexibility. Dividend sustainability looks solid, with a 3.07% yield, a 60% payout ratio, and strong operating cash flow, making the stock attractive for income‑focused investors. However, the utility sector carries inherent regulatory risk, and ED’s high debt‑to‑equity ratio (over 100) warrants monitoring. In summary, the stock offers a stable income stream, modest upside potential, and limited downside, provided regulatory outcomes and debt servicing remain favorable.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish long‑term trend with price above 20‑day SMA
- Negative MACD histogram indicating short‑term pressure
- Increasing volume supporting current price level
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Stable regulated earnings and modest revenue growth
- Attractive dividend yield with sustainable payout
- Current price near fair value with limited upside
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Regulated utility business providing predictable cash flow
- Strong dividend track record and inclusion in Dividend Kings
- Long‑term rate case approvals supporting earnings growth
Key Metrics & Analysis
Financial Health
Revenue Growth8.90%
Profit Margin11.96%
P/E Ratio19.9
ROE8.77%
ROA3.19%
Debt/Equity117.32
P/B Ratio1.7
Op. Cash Flow$4.8B
Free Cash Flow$-145250000
Industry P/E20.8
Technical Analysis
TrendBullish
RSI57.4
Support$106.10
Resistance$115.25
MA 20$111.34
MA 50$106.18
MA 200$101.70
MACDBearish
VolumeIncreasing
Fear & Greed Index78.79
Valuation
Fair Value$113.85
Target Price$110.25
Upside/Downside-1.39%
GradeFair
TypeValue
Dividend Yield3.07%
Risk Assessment
Beta-0.18
Volatility18.55%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.